NCT00740415 - Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

May 31, 2011

Study Completion Date

August 31, 2015

Conditions

Lymphoma

Interventions

BIOLOGICAL

rituximab

Rituximab, 375 mg/m2 Intraveinous

DRUG

bortezomib

-Velcade®, 1,3 mg/m2 Intraveinous on days 1, 4, 8 and 11

DRUG

dexamethasone

day - Dexamethasone, 40 mg Intraveinous

DRUG

Bendamustine

-Day 1 and day 2 Bendamustine/Levact ®,, 90 mg/m2 Intraveinous

Trial Locations (1)

CHU de Grenoble - Hopital Michallon, Grenoble